美股異動 | 豐田跌3% 二季度利潤遜預期
格隆匯8月4日丨豐田(TM.US)跌3.49%,報157.43美元,總市值2160億美元。豐田第一財季營收8.49萬億日元,同比增長7%,超預期的8.17萬億日元;歸母淨利潤7368.2億日元,同比下降17.9%,低於預期的7568億日元;每股盈餘53.65日元,同比下降16.4%;公司表示,儘管日元疲軟帶來了積極的外匯收益,但原材料價格上漲和由於供應緊張造成的銷售量下降,導致營業利潤下降。公司第一財季共售出254.4萬輛汽車,同比下降7.8%,其中28.5%為新能源汽車。展望2023財年,公司將營收指引上調至34.5萬億日元,此前為33萬億;將歸母淨利潤上調至2.36萬億日元,此前為2.26萬億。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.